SLC17A6: A Drug Target and Potential Biomarker for Differentiation-Associated Inorganic Phosphate Cotransporter

Target Name: SLC17A6

NCBI ID: G57084

SLC17A6

Other Name(s): Differentiation-associated Na(+)-dependent inorganic phosphate cotransporter | differentiation-associated Na(+)-dependent inorganic phosphate cotransporter | solute carrier family 17 (vesicular glutamate transporter), member 6 | VGLUT2 | differentiation-associated Na-dependent inorganic phosphate cotransporter | differentiation-associated BNPI | Differentiation-associated BNPI | Vesicular glutamate transporter 2 | solute carrier family 17 member 6 | Differentiation-associated Na-dependent inorganic phosphate cotransporter | VGluT2 | VGLU2_HUMAN | solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 | DNPI | Solute carrier family 17 member 6

SLC17A6: A Drug Target and Potential Biomarker for Differentiation-Associated Inorganic Phosphate Cotransporter

Sodium-dependent inorganic phosphate (Na+-IP) cotransporter 17 (SLC17A6) is a transmembrane protein that plays a crucial role in the regulation of inorganic phosphate homeostasis in various cell types. The SLC17A6 gene has been well-studied, and several studies have identified its involvement in various physiological processes, including cell signaling, protein synthesis, and intracellular signaling pathways. However, its function in the regulation of ion homeostasis and its potential as a drug target or biomarker remain poorly understood.

In this article, we will explore the SLC17A6 gene and its function in the regulation of ion homeostasis, with a focus on its potential as a drug target or biomarker. We will discuss the current understanding of SLC17A6 function and its potential clinical applications, including its potential as a therapeutic target for various diseases, such as cancer, neurodegenerative diseases, and chronic diseases.

SLC17A6 gene and function

SLC17A6 is a member of the family of Na+-ATPases, which are a group of transmembrane proteins that regulate intracellular sodium levels and generate ATP through a unique ATP-dependent mechanism. These proteins play a crucial role in maintaining the resting membrane potential of cells and in the regulation of various physiological processes, including intracellular signaling pathways and protein synthesis.

SLC17A6 is expressed in a variety of tissues and cells, including cardiac muscle, skeletal muscles, liver, and various types of cancer cells. It has been shown to play a role in the regulation of ion homeostasis, specifically in the regulation of intracellular sodium levels and the balance between positive and negative charges within cells.

SLC17A6 is involved in the regulation of several intracellular signaling pathways, including the regulation of protein synthesis, cell signaling, and DNA replication. It has been shown to play a role in the regulation of cell proliferation, cell migration, and the formation of neurotransmitter-dependent neural circuits.

SLC17A6 is also involved in the regulation of ion homeostasis, specifically in the regulation of intracellular sodium levels and the balance between positive and negative charges within cells. It has been shown to play a role in the regulation of action potential generation and propagation, as well as in the regulation of muscle contractions and neuronal excitability.

SLC17A6 as a drug target

SLC17A6 has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and chronic diseases. Its function in the regulation of ion homeostasis and its involvement in various physiological processes make it an attractive target for the development of new therapeutic strategies.

One of the main advantages of SLC17A6 as a drug target is its dual function as a cation transport protein and an ATP-dependent Na+-ATPase. Its ability to regulate intracellular sodium levels and generate ATP through a unique ATP-dependent mechanism makes it a unique target for drug development.

SLC17A6 has been shown to play a role in the regulation of various diseases, including cancer, neurodegenerative diseases, and chronic diseases. For example, studies have shown that SLC17A6 is involved in the regulation of neurotransmitter-dependent neural circuits and that its function in this regulation may be important for the development of neurodegenerative diseases.

Additionally, SLC17A6 has

Protein Name: Solute Carrier Family 17 Member 6

Functions: Multifunctional transporter that transports L-glutamate as well as multiple ions such as chloride, proton, potassium, sodium and phosphate (PubMed:33440152, PubMed:11698620). At the synaptic vesicle membrane, mainly functions as a uniporter which transports preferentially L-glutamate but also, phosphate from the cytoplasm into synaptic vesicles at presynaptic nerve terminals of excitatory neural cells (PubMed:11698620). The L-glutamate or phosphate uniporter activity is electrogenic and is driven by the proton electrochemical gradient, mainly by the electrical gradient established by the vacuolar H(+)-ATPase across the synaptic vesicle membrane (PubMed:11698620). In addition, functions as a chloride channel that allows the chloride permeation through the synaptic vesicle membrane therefore affects the proton electrochemical gradient and promotes synaptic vesicles acidification (By similarity). Moreover, functions as a vesicular K(+)/H(+) antiport allowing to maintain the electrical gradient and to decrease chemical gradient and therefore sustain vesicular glutamate uptake (By similarity). The vesicular H(+)/H(+) antiport activity is electroneutral (By similarity). At the plasma membrane, following exocytosis, functions as a symporter of Na(+) and phosphate from the extracellular space to the cytoplasm allowing synaptic phosphate homeostasis regulation (Probable) (PubMed:10820226). The symporter activity is driven by an inside negative membrane potential and is electrogenic (Probable). Also involved in the regulation of retinal hyaloid vessel regression during postnatal development (By similarity). May also play a role in the endocrine glutamatergic system of other tissues such as pineal gland and pancreas (By similarity)

The "SLC17A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC17A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets